Dapagliflozin vs Durvalumab

Dapagliflozin vs Durvalumab: Overview

This comparison examines the pharmacological differences between Dapagliflozin and Durvalumab.

Mechanism of Action

Dapagliflozin: Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Dapagliflozin — 12.9 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Dapagliflozin — C21H25ClO6.

Molecular Weight: Dapagliflozin — 408.8730 g/mol.

Type: Dapagliflozin — Small molecule; Durvalumab — Antibody.